Get to know our clinical trials
Clinical trial to evaluate the efficacy and safety of TheraSphereTM followed by durvalumab (Imfinzi®) with tremelimumab, versus the use of TheraSphereTM as monotherapy for hepatocellular carcinoma (HCC).
THE OBJECTIVE OF THE STUDY IS TO TEST A NEW TREATMENT FOR YOUR CONDITION. YOUR DOCTOR HAS DETERMINED THAT THERASPHERETM IS AN APPROPRIATE THERAPEUTIC OPTION FOR YOU. THE STUDY WILL DETERMINE WHETHER IT IS SAFE TO ADD THE DRUGS KNOWN AS DURVALUMAB AND TREMELIMUMAB IN IMMUNOTHERAPY FOLLOWING TREATMENT WITH THERASPHERETM AND WHETHER THIS ADDITION IMPROVES THE OUTCOMES OBSERVED WITH THERASPHERETM AS MONOTHERAPY.
Technical Summary
- "RANDOMIZED, PROSPECTIVE, MULTICENTER, OPEN-LABEL CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF THERASPHERETM FOLLOWED BY DURVALUMAB (IMFINZI®) WITH TREMELIMUMAB, VERSUS THE USE OF THERASPHERETM IN MONOTHERAPY FOR HEPATOCELLULAR CARCINOMA (HCC). IMMUNOTHERAPY.
- Code EudraCT: 2021-001907-33
- Protocol number: S2472
- Promoter: Boston scientific
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.